Myovant Sciences Ltd. (MYOV) Financial Analysis & Valuation | Quarter Chart
Myovant Sciences Ltd. (MYOV)
MYOVPrice: $26.98
Fair Value: 🔒
🔒score
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related ... more
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. Th... more
Description
Shares
| Market Cap | $2.62B | Exchange | NYSE |
| Sector | Healthcare | Industry | Biotechnology |
| Country | GB | CEO | David C. Marek |
| IPO Date | 2016-10-27 | CAGR | — |
| Employees | 579 | Website | myovant.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
MYOV chart loading...
Fundamentals
Technicals
| Enterprise Value | $2.73B | P/E Ratio | -14.05 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | 11.36 | P/B Ratio | -5.3 |
| P/CF Ratio | -9.34 | P/FCF Ratio | -9.74 |
| EPS | $-1.92 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 91.46% | Gross Margin | 0.78% |
| Operating Margin | -0.81% | Profit Margin | -0.89% |
| ROE | 0.5% | ROA | -0.4% |
| ROCE | -0.69% | Current Ratio | 1.95 |
| Quick Ratio | 1.92 | Cash Ratio | 1.62 |
| Debt/Equity | -0.78 | Interest Coverage | -13.41 |
| Altman Z Score | -2.96 | Piotroski Score | 2 |